In a report released on April 17, Conor McNamara from RBC Capital maintained a Buy rating on Danaher (DHR – Research Report), with a price target of $284.00. The company’s shares closed yesterday at $236.36.
McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Bio-Rad Laboratories, and Danaher. According to TipRanks, McNamara has an average return of -12.5% and a 29.47% success rate on recommended stocks.
In addition to RBC Capital, Danaher also received a Buy from HSBC’s Rajesh Kumar in a report issued on April 16. However, on April 10, Barclays maintained a Hold rating on Danaher (NYSE: DHR).
The company has a one-year high of $258.72 and a one-year low of $181.70. Currently, Danaher has an average volume of 2.66M.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year. Most recently, in February 2024, Daniel Raskas, the SVP – Corporate Development of DHR sold 23,757.00 shares for a total of $5,986,764.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Danaher (DHR) Company Description:
Founded in 1969 and headquartered in Washington, DC, Danaher Corp. engages in manufacturing, designing and marketing of professional, medical, industrial and commercial products and services. The company operates through three segments, including Life Sciences, Diagnostics, and Environmental & Applied Solutions.
